223 related articles for article (PubMed ID: 24183677)
1. Parkinson's disease patients first treated at age 75 years or older: a comparative study.
Peretz C; Chillag-Talmor O; Linn S; Gurevich T; El-Ad B; Silverman B; Friedman N; Giladi N
Parkinsonism Relat Disord; 2014 Jan; 20(1):69-74. PubMed ID: 24183677
[TBL] [Abstract][Full Text] [Related]
2. Estimation of Parkinson's disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach.
Chillag-Talmor O; Giladi N; Linn S; Gurevich T; El-Ad B; Silverman B; Friedman N; Peretz C
J Neurol; 2013 Jan; 260(1):62-70. PubMed ID: 22772304
[TBL] [Abstract][Full Text] [Related]
3. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset.
Diederich NJ; Moore CG; Leurgans SE; Chmura TA; Goetz CG
Arch Neurol; 2003 Apr; 60(4):529-33. PubMed ID: 12707066
[TBL] [Abstract][Full Text] [Related]
4. Association of time-to-levodopa with initial Parkinsonian medication: a retrospective cohort study.
Reese JP; Hamer H; Oertel WH; Strzelczyk A; Mueller UO; Heilmaier C; Kostev K
Int J Clin Pharmacol Ther; 2015 Feb; 53(2):107-14. PubMed ID: 25546160
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.
Graham DJ; Williams JR; Hsueh YH; Calia K; Levenson M; Pinheiro SP; Macurdy TE; Shih D; Worrall C; Kelman JA
Mov Disord; 2013 Apr; 28(4):490-7. PubMed ID: 23443994
[TBL] [Abstract][Full Text] [Related]
6. Use of a refined drug tracer algorithm to estimate prevalence and incidence of Parkinson's disease in a large israeli population.
Chillag-Talmor O; Giladi N; Linn S; Gurevich T; El-Ad B; Silverman B; Friedman N; Peretz C
J Parkinsons Dis; 2011; 1(1):35-47. PubMed ID: 23939255
[TBL] [Abstract][Full Text] [Related]
7. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
[TBL] [Abstract][Full Text] [Related]
8. [The use of antiparkinsonism drugs in 92 cases in Xi'an city].
Zhe X; Qu QM; Wang RL; Cao HM; Qiao J; Guo F
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Oct; 30(10):1065-8. PubMed ID: 20193391
[TBL] [Abstract][Full Text] [Related]
9. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.
De Reuck J; De Weweire M; Van Maele G; Santens P
J Neurol Sci; 2005 Apr; 231(1-2):35-9. PubMed ID: 15792818
[TBL] [Abstract][Full Text] [Related]
10. The natural history of Parkinson's disease in the province of Segovia: mortality in a longitudinal study (20-year follow-up).
Duarte J; García Olmos LM; Mendoza A; Clavería LE
Acta Neurol Scand; 2013 May; 127(5):295-300. PubMed ID: 22957805
[TBL] [Abstract][Full Text] [Related]
11. Levodopa fractionation in Parkinson's disease.
Nyholm D; Stepien V
J Parkinsons Dis; 2014; 4(1):89-96. PubMed ID: 24398654
[TBL] [Abstract][Full Text] [Related]
12. Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease.
Wagner ML; Fedak MN; Sage JI; Mark MH
Ann Clin Lab Sci; 1996; 26(5):389-95. PubMed ID: 8879356
[TBL] [Abstract][Full Text] [Related]
13. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease.
Mokhles MM; Trifirò G; Dieleman JP; Haag MD; van Soest EM; Verhamme KM; Mazzaglia G; Herings R; Luise Cd; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; Camp Gv; Zanettini R; Sturkenboom MC
Pharmacol Res; 2012 Mar; 65(3):358-64. PubMed ID: 22123498
[TBL] [Abstract][Full Text] [Related]
14. [Progress in the basic and clinical aspects of Parkinson's disease].
Mizuno Y
Rinsho Shinkeigaku; 2004 Nov; 44(11):741-50. PubMed ID: 15651281
[TBL] [Abstract][Full Text] [Related]
15. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.
Olanow CW; Kieburtz K; Stern M; Watts R; Langston JW; Guarnieri M; Hubble J;
Arch Neurol; 2004 Oct; 61(10):1563-8. PubMed ID: 15477510
[TBL] [Abstract][Full Text] [Related]
17. Othello syndrome in patients with Parkinson's disease.
Georgiev D; Danieli A; Ocepek L; Novak D; Zupancic-Kriznar N; Trost M; Pirtosek Z
Psychiatr Danub; 2010 Mar; 22(1):94-8. PubMed ID: 20305599
[TBL] [Abstract][Full Text] [Related]
18. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
[TBL] [Abstract][Full Text] [Related]
19. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
[TBL] [Abstract][Full Text] [Related]
20. Clinical course of patients with idiopathic Parkinson's disease.
Roos RA; Jongen JC; van der Velde EA
Mov Disord; 1996 May; 11(3):236-42. PubMed ID: 8723138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
